STK321130 (FLT3-IN-2) is primarily used in research and development for targeting FLT3 mutations, which are commonly associated with acute myeloid leukemia (AML). It acts as a potent inhibitor of FLT3 tyrosine kinase, making it a valuable tool in studying the mechanisms of FLT3-driven cancers. Researchers utilize this compound to explore potential therapeutic strategies, particularly in preclinical studies, to assess its efficacy in inhibiting cancer cell proliferation and inducing apoptosis. Its application extends to drug discovery programs aimed at developing targeted therapies for AML and other hematologic malignancies. Additionally, it serves as a reference compound in biochemical assays to evaluate the activity of other FLT3 inhibitors.